NCT07060950Not yet recruiting
Analysis of Circulating Tumor Markers in Blood - ALCINA 5
Source: ClinicalTrials.gov · Last updated 19 Sept 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The circulating tumoral biomarkers in the blood are the object of numerous researches for several decades. The potential clinical interests of these circulating biomarkers are diagnostic, prognostic, predictive of the efficiency of targeted therapies (according to the mutational profile of the cancer), and could allow the study of the mechanisms of resistance under process. In the multiplicity of these blood potential biomarkers joins a permanent evolution of the technological means used to detect them/to quantify, as well as to estimate their clinical utility.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 620 (estimated)
- First submitted
- 2 Jul 2025
- Start date
- 1 Oct 2025
- Primary completion date
- 31 Jul 2030
- Lead sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
- Diseases
- Lung cancer
- NCT number
- NCT07060950
What you commit to
- Study type: Interventional
- Planned participants: 620
- From 1 Oct 2025 to the primary completion date, 31 Jul 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patient with a history of other invasive cancers within the 5 years preceding inclusion.
Other
- Pregnant woman and/or breast-feeding,
- Patient whose regular follow-up is impossible for psychological, family, social or geographical reasons,
- Private persons of freedom or under guardianship,
Who the study is looking for
- Patient presenting an invasive tumoral pathology (proved or suspected), whatever is the location or the stage,
- 18 years old or higher ?
- Patient who has provided informed, written, and explicit consent,
- Patient affiliated with a French Social Protection System.
- In the case of a tumor biopsy:
- Tumor considered as accessible by biopsy,
- Normal hemostasis assessment (PT, APTT, platelets),
- No anticoagulant or antiaggregant treatment for the biopsy.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle Coordinator of this site? Confirm its status | Montpellier | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.